The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Open accessThe DOI matches its Crossref record; 119 of the 140 references it cites were found in a registry or an index; 9 of the 77 sources its claims cite were checked for support.
Abstract
OBJECTIVE: The objective of the study was to develop clinical practice guidelines for the diagnosis of Cushing's syndrome. PARTICIPANTS: The Task Force included a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, five additional experts, a methodologist, and a medical writer. The Task Force received no corporate funding or remuneration. CONSENSUS PROCESS: Consensus was guided by systematic reviews of evidence and discussions. The guidelines were reviewed and approved sequentially by The Endocrine Society's CGS and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage the Task Force incorporated needed changes in response to written comments. CONCLUSIONS: After excluding exogenous glucocorticoid use, we recommend testing for Cushing's syndrome in patients with multiple and progressive features compatible with the syndrome, particularly those with a high discriminatory value, and patients with adrenal incidentaloma. We recommend initial use of one test with high diagnostic accuracy (urine cortisol, late night salivary cortisol, 1 mg overnight or 2 mg 48-h dexamethasone suppression test). We recommend that patients with an abnormal result see an endocrinologist and undergo a second test, either one of the above or, in some cases, a serum midnight cortisol or dexamethasone-CRH test. Patients with concordant abnormal results should undergo testing for the cause of Cushing's syndrome. Patients with concordant normal results should not undergo further evaluation. We recommend additional testing in patients with discordant results, normal responses suspected of cyclic hypercortisolism, or initially normal responses who accumulate additional features over time.
Overview
CoChat Summary
TL;DR
This Endocrine Society guideline recommends case detection for Cushing's syndrome only in selected high-risk groups, initial testing with one of four high-accuracy tests, and confirmatory second testing before cause-directed evaluation. It emphasizes excluding exogenous glucocorticoids first and notes that most recommendations rest on very low- to low-quality evidence.
Key findings
- Exclude exogenous glucocorticoid exposure before biochemical testing (1QQQQ); test patients with multiple and progressive features, unusual features for age, children with decreasing height percentile and increasing weight, or adrenal incidentaloma compatible with adenoma, and recommend against widespread testing in other groups.
- Initial testing should use one of: urine free cortisol (at least two measurements), late-night salivary cortisol (two measurements), 1-mg overnight dexamethasone suppression test, or 48-h 2 mg/d dexamethasone suppression test; recommend against random serum cortisol/plasma ACTH, urinary 17-ketosteroids, insulin tolerance test, loperamide test, and cause-directed tests for initial diagnosis.
- Reported test performance includes late-night salivary cortisol sensitivity 92–100% and specificity 93–100%; pediatric UFC sensitivity about 89%; 1-mg DST at a 1.8 µg/dL cutoff sensitivity >95% with specificity 80%, rising to >95% specificity at a 5 µg/dL threshold; LDDST sensitivity 96% and specificity 70%; dexamethasone-CRH sensitivity 98% and specificity 60%.
- Special-population recommendations: use UFC and avoid dexamethasone testing in pregnancy; avoid dexamethasone testing with enzyme-inducing antiepileptics; suggest 1-mg overnight DST rather than UFC in severe renal failure; suggest UFC or midnight salivary cortisol rather than DSTs in suspected cyclic Cushing's; suggest 1-mg DST or late-night cortisol rather than UFC in adrenal incidentaloma.
Methods
- A six-member Task Force appointed by The Endocrine Society's Clinical Guidelines Subcommittee, including a chair, five additional experts, a methodologist, and a medical writer, received no corporate funding or remuneration; consensus was guided by systematic reviews and discussions and approved sequentially by Society bodies and members.
- Recommendations used the GRADE approach: strong recommendations phrased “we recommend” with number 1, weak recommendations “we suggest” with number 2; evidence quality ranged from QEEE (very low) to QQQQ (high), informed by best available research evidence and systematic reviews/meta-analyses of test accuracy.
- The guideline presents evidence, values, and remarks linked to each recommendation; technical remarks often reflect the panel's unsystematic observations applied to a typical patient.
Limitations
- Stated: the majority of recommendations are based on very low- to low-quality evidence, with limited data linking diagnostic strategies to patient-important outcomes and no higher-quality direct evidence available.
- Stated: published data often come from larger tertiary referral centers and may be biased toward more diagnostically challenging cases, higher pretest probability, and greater disease severity, potentially giving an overly sanguine view of test performance in unselected populations.
- Evident from the text: this is a consensus guideline rather than a primary study, and some technical recommendations rest on unsystematic panel observations; data on treating mild/subclinical Cushing's syndrome and adrenal incidentaloma are described as limited and conflicting.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 4 Not valid · 37 Not checked · 33 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Another study of 86 consecutive obese subjects referred to an endocrine clinic with diabetes mellitus, hypertension, and/or the polycystic ovary syndrome found a 5.8% incidence of Cushing's syndrome (35).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.3 Evidence
What the sources say
- Partly supportedcites [35] 35. Ness-Abramof R, Nabriski D, Apovian CM, Niven M, Weiss E, Shapiro MS, Shenkman L 2002 Overnight dexamethasone suppression test: a reliable screen for Cushing's syndrome in the obese. Obes Res 10:1217-1221 sourceExperimental — accuracy not yet measured
The Patients section describes 86 obese patients referred to an endocrine clinic, and the Results report five Cushing’s syndrome diagnoses—5/86, or approximately 5.8%, though the paper prints 5.7%. The copy does not say the patients were consecutive. It also reports that 51 had obesity alone, so diabetes, hypertension, and polycystic ovary disease do not describe the whole group. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The salivary glands express 11-hydroxysteroid dehydrogenase type 2 (11-HSD2), which converts the biologically active cortisol to inactive cortisone (75).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Remarks for late-night salivary cortisol
What the sources say
- Supportedcites [75] 75. Smith RE, Maguire JA, Stein-Oakley AN, Sasano H, Takahashi K, Fuku- shima K, Krozowski ZS 1996 Localization of 11-hydroxysteroid dehydro- genase type II in human epithelial tissues. J Clin Endocrinol Metab 81:3244 - 3248 source
The paper reports 11β-HSD2 in the ducts of human parotid and submandibular salivary glands (Abstract; Discussion, p. 3247). It describes the enzyme as inactivating glucocorticoids and discusses salivary cortisol-to-cortisone ratios (Introduction; Discussion, p. 3247), supporting the stated function. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Overall, the evidence in adults suggests that the accuracy of this test is similar to that of UFC (2).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.2 Evidence for late-night salivary cortisol
What the sources say
- Supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 source
Table 3 (Conclusions; page unavailable) reports broadly similar pooled diagnostic likelihood ratios for midnight salivary cortisol and UFC. The Summary of findings notes that evidence for salivary cortisol is more limited, consistent with the citing sentence’s cautious wording. (LLM, conf=0.88)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“When the assay upper limit of normal is used as a criterion, the overall evidence supports the diagnostic accuracy of UFC in adults suspected of having Cushing's syndrome (2,51).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4.1 Evidence for use of UFC
What the sources say
- Partly supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 sourceExperimental — accuracy not yet measured
The Summary of findings says UFC has substantial evidence supporting its use to detect Cushing’s syndrome, and the pooled results table reports diagnostic accuracy across 14 UFC studies. The Subgroup analyses section identifies an assay-upper-limit cutoff, but the reported UFC estimate is pooled across studies rather than shown specifically for that cutoff. The Conclusions also limit the apparent accuracy to referral practices enriched with patients with Cushing’s syndrome; performance in usual clinical practice remains unclear. Page numbers were not available in our copy. (LLM, conf=0.83)
- Supportedcites [51] 51. Pecori Giraldi F, Ambrogio AG, De Martin M, Fatti LM, Scacchi M, Cav- agnini F 2007 Specificity of first-line tests for the diagnosis of Cushing's syndrome: assessment in a large series. J Clin Endocrinol Metab 92:4123- 4129 source
The UFC results (p. 2) report 91.2% specificity in Cushing’s syndrome suspects when values above the assay’s reference range were considered abnormal. The Discussion (p. 5) identifies that threshold as the assay’s upper limit of normal and describes UFC as having superior diagnostic performance. The study assessed specificity, rather than diagnostic accuracy across all measures. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The four recommended tests have acceptable diagnostic accuracy when the suggested cutoff points are used (2,30).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.4 Evidence
What the sources say
- Partly supportedcites [2] 2. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ, Montori VM 2008 Accuracy of diagnostic tests for Cushing syndrome: a systematic review and meta-analyses. J Clin Endocrinol Metab 93:1553-1562 sourceExperimental — accuracy not yet measured
The Conclusions state that commonly used tests appear highly accurate in referral practices with samples enriched for Cushing’s syndrome, but that their performance in usual clinical practice is unclear. The Data extraction section says the review used cutoffs chosen by the primary studies, selecting those with the best performance when several were available; it does not establish accuracy specifically at the suggested cutoff points. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [30] 30. Batista DL, Riar J, Keil M, Stratakis CA 2007 Diagnostic tests for children who are referred for the investigation of Cushing syndrome. Pediatrics 120: e575-e586 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
48 more claims · 3 with their cited sources checked
Create a free account to see all 82 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 12
- It may state two separate claims as one. 20
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early diagnosis of secondary hypertension and the institution of appropriate targeted treatment have the potential to cure hypertension in some patients or improve BP control/reduce the number of prescribed antihypertensive medications in others.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [118]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, accurate serum cortisol measurement is essential for the correct diagnosis and management of adrenal pathologies.”
From Serum cortisol: an up-to-date assessment of routine assay performance (2016) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the reliability of almost all markers of HPA axis activity, particularly ACTH and 24-h urinary free cortisol (UFC), is low (3,14,23)”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, UFC should not be considered an adequate screening test for SH and should be used in combination with other tests or in specific populations (1,14).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“some authors have proposed higher (3 or 8 mg) dexamethasone doses (40,46,54,56), which however did not show a better performance (14,23,66).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [14]
Experimental — accuracy not yet measured
27 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“biochemical hypercortisolism is present in a large fraction (up to 10%).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > 3.2 Evidence
“Libe et al. (32) reported 18%; Terzolo et al. (21) quoted 5-20%, depending on referral bias and diagnostic tests and criteria.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > Subsequent evaluation
“3.9.1 We suggest the additional use of the dexamethasone-CRH test or the midnight serum cortisol test in specific situations (Fig. 1, 1QEEE).”
§ The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline > METHOD OF DEVELOPMENT OF EVIDENCE-BASED RECOMMENDATIONS
“strong recommendations use the phrase "we recommend" and the number 1, and weak recommendations use the phrase "we suggest" and the number 2.”
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“with expertise in development and implementation of evidencebased guidelines (1).”
BackgroundCushing, H. (1964) · Journal of Neurosurgery · doi:10.3171/jns.1964.21.4.0318 · Cited by 851 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundThe Diagnosis and Differential Diagnosis of Cushing’s Syndrome and Pseudo-Cushing’s States
Newell-Price, J., Trainer, P., Besser, M., & Grossman, A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0346 · Cited by 833
Self-citationGold, P. W., Loriaux, D. L., Roy, A., Kling, M. A., Calabrese, J. R., Kellner, C. H., Nieman, L. K., Post, R. M., Pickar, D., Gallucci, W., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198605223142101 · Cited by 766
Self-citationThe natural history of cushing's syndrome
Plotz, C. M., Knowlton, A. I., & Ragan, C. (1952) · The American Journal of Medicine · doi:10.1016/0002-9343(52)90027-2 · Cited by 763 · cited 1×
“6 yr, and in 1952 a 5-yr survival of just 50%, with most deaths caused by vascular (myocardial infarction, cerebrovascular accident) or infectious complications (11, 12).”
BackgroundTESTS OF PITUITARY-ADRENAL SUPPRESSIBILITY IN THE DIAGNOSIS OF CUSHING'S SYNDROME*
LIDDLE, G. W. (1960) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-20-12-1539 · Cited by 735
Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease
Wei, L., MacDonald, T. M., & Walker, B. R. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00007 · Cited by 730 · cited 1×
“These data are consistent with the increased cardiovascular mortality and morbidity reported in patients with iatrogenic Cushing’s syndrome secondary to the chronic use of synthetic corticosteroids (15).”
ResultMeasurements of Serum Free Cortisol in Critically Ill Patients
Hamrahian, A. H., Oseni, T. S., & Arafah, B. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa020266 · Cited by 726 · cited 1×
“are associated with decreased serum cortisol values (39, 46).”
BackgroundMorbidity and mortality in Cushing's disease: an epidemiological approach.
Etxabe, J., & Vazquez, J. A. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02486.x · Cited by 622 · cited 2×
“0-fold, compared with the general population (4, 5).”
BackgroundIncidence and Late Prognosis of Cushing’s Syndrome: A Population-Based Study1
Lindholm, J., Juul, S., Jørgensen, J. O. L., Astrup, J., Bjerre, P., Feldt-Rasmussen, U., Hagen, C., Jørgensen, J., Kosteljanetz, M., Kristensen, L. Ø., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7093 · Cited by 619 · cited 6×
“Because some patients with Cushing’s disease demonstrate suppressibility to dexamethasone, use of this diagnostic criterion J Clin Endocrinol Metab, May 2008, 93(5):1526–1540 jcem.”
BackgroundInfluential
Cited by
Items 2,201–2,300 of 2,716
Alerraqi, E. (2016) · Revue de Stomatologie de Chirurgie Maxillo-faciale et de Chirurgie Orale · doi:10.1016/j.revsto.2016.08.001
Endocrine disorders in the elderly
Yalamanchi, S., Tabatabai, L. S., & Moseley, K. F. (2016) · Cambridge University Press eBooks · doi:10.1017/cbo9781107294967.029
Long-term steroid hormone concentrations in healthy children, in obesity, and in disease
Noppe, G. (2016) · EUR Research Repository (Erasmus University Rotterdam)
New onset Sarcoidosis following treatment of Cushing's Disease
Cairns, R. A., & Hall, L. (2016) · Endocrine Abstracts · doi:10.1530/endoabs.44.ep59
“[1] In rare cases the treatment of Cushing’s Disease, with a subsequent reduction in glucocorticoid concentration, may result in the unveiling or aggravaion of a disease responsive to glucocorticoid therapy.”
BackgroundScheckel, K. A. (2016) · Physician Assistant Clinics · doi:10.1016/j.cpha.2016.08.010
Carşote, M., Ghemigian, A. M., Valea, A., Dumitrascu, A. S., Chiriţă, C., & Poiană, C. (2015) · Ars medica tomitana · doi:10.1515/arsm-2015-0032 · Cited by 8
“[10] The computer tomography (CT) showed two adrenal masses of 1.”
MethodEpidemiology and Etiology of Cushing’s Disease
Tritos, N. A., & Biller, B. M. K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804340-0.00002-4
Self-citationBueno, C. B. F. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2017.tde-18012017-143730
Auchus, R. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-385157-4.01208-2
Nieman, L. K. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00234-7 · Cited by 1
Self-citationЩекатурова, Л. В., Товкай, О. А., & Третяк, О. Е. (2015) · Clinical endocrinology and endocrine surgery · doi:10.24026/1818-1384.3(51).2015.75151
A Case of Cushing’s Syndrome Presented with Severe Heart Failure and Multiple Vertebral Fractures
Arduç, A., Işık, S., Akbaba, G., Küçükler, K., Berker, D. S., & Güler, S. (2015) · Medical Bulletin of Haseki · doi:10.4274/haseki.2473
Scharitzer, M., Tamandl, D., & Ba‐Ssalamah, A. (2017) · Der Radiologe · doi:10.1007/s00117-017-0236-9
Labordiagnostik bei arterieller Hypertonie
Tomaschitz, A., Pilz, S., & März, W. (2017) · Der Klinikarzt · doi:10.1055/s-0043-104687
Síndrome de Cushing Ectópica: Um Desafio Diagnóstico e Terapêutico
Fernandes, V., Monteiro, A. M., Santos, M. J., et al. (2018) · Gazeta Médica · doi:10.29315/gm.v5i1.141
Endocrine Hypertension and Chronic Kidney Disease
Koch, C. A., Pamporaki, C., & Kantorovich, V. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1982-6_16 · Cited by 1
Análise da expressão gênica diferencial entre microcorticotropinomas e macrocorticotropinomas
de Araújo, L. J. T. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2017.tde-03052017-155212
An approach to screening for Cushing's syndrome in non-specialized health care settings
Cano, D. A., & Leal‐Cerro, A. (2017) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2017.04.003
“The Endocrine Society guidelines recommend relying on clinical suspicion, and to screen for CS only in patients with highly suggestive signs and symptoms.(7) However, it is unclear which particular patients should be screened.”
MethodBatista, S. L. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2017.tde-30032017-085813
Young, W. F. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42973-3.00014-7
Urmanova, Y. М., Khalimova, Z., Narimova, G., Madaminova, H. R., Abduvakhabova, M., Alieva, D., Kholova, D. S., Alimukhamedova, H. O., Карімова, М. М., Khodjayeva, F. S., et al. (2021) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.13.3.2017.104112
Nonfunctional Adrenal Adenomas: Truth or Myth? Presentation and Treatment of 2 Patients
Moraitis, A. G. (2017) · AACE Clinical Case Reports · doi:10.4158/ep171897.cr
Upton, T. J., & Lightman, S. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64285-x
Saleh, L. (2017) · Praxis · doi:10.1024/1661-8157/a002832
Adrenal Cushing’s Syndrome: Updates on Overt and Mild Hypercortisolism
Escobar, J. S., Ravikumar, A., & Levine, A. C. (2017) · Contemporary Endocrinology · doi:10.1007/978-3-319-62470-9_10
Circadian clock mechanisms in adrenal adenomas are not related to osteopenia and osteoporosis
Katsoulis, K., Ioannidis, D., Karageorgos, G., & Lambrou, G. Ι. (2017) · Journal of Research and Practice on the Musculoskeletal System · doi:10.22540/jrpms-01-031
Hypophysenadenome – nicht immer benigner Natur
Petersenn, S. (2017) · Der Onkologe · doi:10.1007/s00761-017-0319-2
Physiopathology, Diagnosis, and Treatment of Hypercortisolism
Pivonello, R., Iacuaniello, D., Simeoli, C., Martino, M. C. D., & Colao, A. (2017) · Endocrinology · doi:10.1007/978-3-319-38681-2_12-1
Screening For Cushing's Syndrome in Primary Care: Which Test is The Best?
Naik, V. (2017) · Current Research in Diabetes & Obesity Journal · doi:10.19080/crdoj.2017.02.555585
“This test is usually considered overall to have a high diagnostic sensitivity in adults and children, it is important to correlate test results with creatinine ratios to ensure a complete collection [4].”
BackgroundInfluentialCushing’s disease: is pasireotide LAR a breakthrough in adjuvant therapy after unsuccessful surgery?
Witek, P., Mazur, M., & Witek, J. (2017) · Oncoreview · doi:10.24292/01.or.211217
“It may also be indicated in cases of severe hypercortisolism as an element of patient preparation for surgical treatment, as it reduces disease symptoms and complications [2, 3].”
BackgroundWilkinson, I. C. E., Savage, M. O., & Storr, H. L. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65338-2
Self-citationKaruppiah, D., Cooray, M., Somasundaram, N. P., & Ediriweera, D. (2018) · International Journal of Advanced Research · doi:10.21474/ijar01/6262
“Duration of T2DM (year) 16(15-18) 12(8-17) 0.”
Non abbassare la guardia nel sospetto di Sindrome di Cushing ciclica
Ferraù, F., & Cannavò, S. (2018) · L Endocrinologo · doi:10.1007/s40619-018-0421-8
Gasser, Μ., & Meier, C. A. (2016) · Swiss Medical Forum ‒ Schweizerisches Medizin-Forum · doi:10.4414/smf.2016.02681
Surgical Considerations in Subclinical Cushing’s Syndrome. When is it Time to Operate?
Nixon, A. M., Aggeli, C., Tserkezis, C., & Zografos, G. (2018) · Hellenic Journal of Surgery · doi:10.1007/s13126-018-0431-9
“Using as a starting point the original National Institute of Health (NIH) guidelines published in 2002, there have been at least 5 separate attempts by various prestigious medical societies to define cortisol secretion autonomy [18-21].”
MethodLa terapia medica della Malattia di Cushing: presente e futuro
Ceccato, F., Lizzul, L., & Scaroni, C. M. (2018) · L Endocrinologo · doi:10.1007/s40619-018-0441-4
“Le linee guida raccomandano per la diagnosi di CS il dosaggio del cortisolo libero urinario (urinary free cortisol, UFC) in 2 determinazioni: la determinazione del ritmo del cortisolo (possibilmente salivare in 2 misurazioni) o il test di soppressione con 1 mg di desametazone [1].”
BackgroundCushing Syndrome; Screening and Differential Diagnosis
Lacroix, A., & Nieman, L. K. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65857-9
Self-citationRamachandran, R., Alaghband‐Zadeh, J., Sankaralingam, A., Khan, S. A., Tavabie, M., Fernyhough, C., Sabry, M., Maghsoodi, N., McGowan, B. M., Carroll, P., et al. (2017) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563217732361
“CI results in a decrease in total (T) and early morning peak cortisol (S2, S3) and in a blunting of response to circadian rhythm/sleep as a physiological stimulus (V).(5) We have reliably demonstrated all three using noninvasive MTSUCT.”
BackgroundMethodPituitary Tumors: Viewpoint— Medical Therapy
Hopkins, R. L. (2015) · Springer eBooks · doi:10.1007/978-1-4614-8363-2_29
Sickler, T. D. P. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2018.tde-08052018-083923 · Cited by 2
Cushing’s Disease: An Historical Perspective
Aron, D. C. (2011) · Endocrine updates · doi:10.1007/978-1-4614-0011-0_1
“reported on the development of a consensus approach to the treatment of patients with ACTH-dependent Cushing’s disease [37, 48].”
BackgroundHyperkortisolismus – Cushing-Syndrom
Schulte, H. M., & Kamphausen, K. (2010) · Elsevier eBooks · doi:10.1016/b978-3-437-24680-7.10026-1
Modarelli, R. E., & Stephen, M. D. (2018) · AACE Clinical Case Reports · doi:10.4158/accr-2018-0224
Rationelles Screening bei Nebennierentumoren
Willenberg, H. S., & Kupfer, S. (2018) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0043-121019
“Glukokortikoidexzess Mineralokortikoidexzess Katecholaminexzess Nieman et al. 2008 [9] Funder et al. 2016 [10] Lenders et al. 2014 [11] Plouin et al. 2016 [12] exogene Glukokortikoide Aliskiren trizyklische Antidepressiva CYP3A4-Interferenzen Betablocker, Clonidin, NSAR MAO-Inhibitoren Östrogene…”
BackgroundCastinetii, F. (2010) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2010.91
Adrenal Function and Skeletal Regulation
Chiodini, I., Battista, C., Cairoli, E., Eller-Vainicher, C., Morelli, V., Palmieri, S., Salcuni, A. S., & Scillitani, A. (2018) · Springer eBooks · doi:10.1007/978-3-319-75110-8_7
Cushing’s Disease: Common Pitfalls in Diagnosis
Fazeli, P. K. (2018) · Springer eBooks · doi:10.1007/978-3-319-90909-7_4
Hwang, A. Y. (2017) · The American Pharmacists Association eBooks · doi:10.21019/pharmacotherapyfirst.adrenal_overview
Rumsby, G. (2018) · Springer eBooks · doi:10.1007/978-3-319-96364-8_16
Cavalcanti, M. M. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2018.tde-24042018-164945
Fortschritte in der Endokrinologie: Was für den Hausarzt wichtig ist
Schmidmaier, R., & Reincke, M. (2018) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-018-1123-7
“Der Verdacht auf das Vorliegen eines Cushing-Syndroms muss geäußert werden, wenn bei einer sorgfältigen Ganzkörperuntersuchung die charakteristischen Stigmata an der Haut (Rubeosis, Akne, Hämatomneigung, Hirsutismus, Infektionen, breite livide Striae) und Zeichen der veränderten Fettgewebsverteilung (Mondgesicht, Zuna…”
BackgroundКомбіновані оральні контрацептиви: оптимальний комплекс обстеження. Частина 2
Рыкова, О. В. (2021) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.14.7.2018.149770
Neuroendocrine Disorders in Women
Lovett, A. J., & Woodmansee, W. W. (2019) · Springer eBooks · doi:10.1007/978-3-030-04245-5_5
Cushing’s Syndrome and Disease
Moore, E. C., & Krishnamurthy, V. D. (2019) · Springer eBooks · doi:10.1007/978-3-319-98497-1_110
Комбіновані оральні контрацептиви: оптимальний комплекс обстеження. Частина 1
Рыкова, О. В. (2018) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.14.6.2018.146072
ACTH Producing Adenomas: Cushing’s Disease
McGlotten, R., Adelman, D. T., & Keil, M. F. (2019) · Springer eBooks · doi:10.1007/978-3-319-99817-6_21
Arseneau, N., & Muzlera, C. U. (2016) · University of Western Ontario Medical Journal · doi:10.5206/uwomj.v85i1.4239
Other Pituitary Disorders and Kidney Disease
Huang, W., & Molitch, M. E. (2019) · Springer eBooks · doi:10.1007/978-3-319-97765-2_22
Диагностика и лечение гипофизарного синдрома Кушинга
Kirilyuk, M. L. (2014) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.6.62.2014.76950
4 Functional and Nonfunctional Pituitary Adenomas
Chandra, A., & Aghi, M. K. (2019) · Springer eBooks · doi:10.1007/978-3-319-64379-3_4
Hauffa, B. P., Binder, G., Bonfig, W., Bettendorf, M., & Dörr, H. G. (2019) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-019-0697-1
Інциденталоми надниркових залоз: діагностика та вибір тактики ведення хворих
Луценко, Л. А., & Kvachenyuk, D. A. (2014) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.4.60.2014.76686
A rare case of duodenal carcinoid presenting as ectopic Cushing’s syndrome
Pugalendhi, S., Dutta, T. K., Dhivya, & Yadav, K. (2019) · International Journal of Advances in Medicine · doi:10.18203/2349-3933.ijam20192270
Lechner, B., Heinrich, D. A., Nölting, S., Osswald-Kopp, A., Rubinstein, G., Sauerbeck, J., Beuschlein, F., & Reincke, M. (2019) · Zentralblatt für Arbeitsmedizin Arbeitsschutz und Ergonomie · doi:10.1007/s40664-019-0342-9
Adrenal incidentaloma: management of patients with functionally autonomous cortisol synthesis
Chzhen, T. R., Киселева, Т. П., & Торосян, М. Р. (2019) · Kazan medical journal · doi:10.17816/kmj2019-277
A Stratified Approach for Cushing’s Syndrome Diagnosis
Chávez-Castillo, M., Rojas, J., Aguirre, M., Villalobos, M., Salazar, J. J., Bello, L., Áñez, R., Olivar, L. C., Calvo, M. C. C., Herazo-Beltrán, Y., et al. (2019) · Global Journal of Health Science · doi:10.5539/gjhs.v11n10p55
“Exclusion of Physiological Causes of Hypercortisolism If the previous procedures confirm hypercortisolism, the exclusion of its physiological causes is recommended (Table 4), as they may be conditioning chronic hypersecretion of this hormone in the absence of histologic alterations within the components of the HHAA (N…”
BackgroundInfluentialSeptar, A., Ilie, I., Tulin, A. D., Terzea, D. C., Hortopan, D., Goldstein, A. L., Chiriac, I. A., Ţupea, C., Oprea, L., Banica, A., et al. (2019) · ROMANIAN BIOTECHNOLOGICAL LETTERS · doi:10.25083/rbl/24.4/736.741
“Widespread screening for CS in overweight individuals or patients with type 2 diabetes mellitus is therefore not recommended [11].”
BackgroundTherapy of mild cortisol excess
Iqbal, A., & Newell-Price, J. D. C. (2019) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2019.08.019
Self-citationLeibovitz, E., & Cohen, B. D. (2015) · The FASEB Journal · doi:10.1096/fasebj.29.1_supplement.710.19
Pseudo-Cushing’s Syndrome: A Diagnostic Dilemma
Brown, T. V., Belokovskaya, R., & Pessah‐Pollack, R. (2019) · Springer eBooks · doi:10.1007/978-3-030-22720-3_13
Tanno, F. Y. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2019.tde-18112019-110029
Dexamethasone Suppression Test
Dogra, P., & Vijayashankar, N. P. (2019) · StatPearls · Cited by 6
RELATO DE CASO DE SECREÇÃO ECTÓPICA DE HORMÔNIO ADRENOCORTICOTRÓFICO: UM DESAFIO DIAGNÓSTICO
Miranda, I. S. D. M., & Azevedo, M. F. (2015) · Brasília Médica · doi:10.5935/2236-5117.2015v52n3/4a08
2. Diagnosis and Treatment of Endocrine Hypertension
Shibata, H. (2019) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.108.452
Kirnap, N. G., Öztekin, S., & Tütüncü, N. B. (2020) · Dicle Medical Journal / Dicle Tip Dergisi · doi:10.5798/dicletip.706119
Pediatric cyclical Cushing’s disease: a case report and literature review
Solntsava, A. V., Volkava, N. V., Beliayeva, K. A., & Zhurauliou, V. A. (2020) · Ukrainian Journal of Pediatric Endocrinology · doi:10.30978/ujpe2020-1-47
Galm, B. P., & Tritos, N. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-38976-5_18
(2017) · Elsevier eBooks · doi:10.1016/b978-3-437-23316-6.00003-3
Samuels, M. H. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-4975-1.00032-2
Bithal, P. K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805299-0.00022-1
Spratt, S. E., & Woodmansee, W. W. (2011) · Elsevier eBooks · doi:10.1016/b978-0-323-06398-2.00017-5
Akın, Ş., Dağdelen, S., Yıldız, B. O., Gürlek, A., Erbas, T. A., & Bayraktar, M. (2020) · Kocatepe tıp dergisi. · doi:10.18229/kocatepetip.507301
Wu, C., Zhang, H., Fan, C., Wu, P., Wei, Q., Cai, Y., Zou, S., Wang, L., Xue, Y., & Guan, M. (2016) · Europe PMC (PubMed Central) · doi:10.3969/j.issn.1673-4254.2017.04.25
Megacolon en el contexto de síndrome de Cushing de larga evolución
López, L. M., Beltrán, L. M., Cruz, M. Á. M., López, A. P., & Delgado, D. A. (2020) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2020.02.004
CME: Endogener Hyperkortisolismus (endogenes Cushingsyndrom)
Fischli, S. (2020) · Praxis · doi:10.1024/1661-8157/a003465
Seltene Ursache einer arteriellen Hypertonie
Meier, M. A., Gaisl, T., & Schmidt, D. (2020) · Praxis · doi:10.1024/1661-8157/a003398
Manni, A., & Quarde, A. (2020) · Springer eBooks · doi:10.1007/978-3-030-49872-6_1
Sarda, Y., Shenoy, D., Shetty, S. P., Ullal, S., & Katyal, S. (2020) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_230_20
Ривгатовна, Ш. З., Великанова, Л. И., Ворохобина, Н. В., Валерьевна, М. Е., Геннадьевна, С. Е., & Pal’cman, Z. V. (2020) · Russian Clinical Laboratory Diagnostics · doi:10.18821/0869-2084-2020-65-7-418-423
An Introduction to Sellar Masses
Wilkinson, M., & Imran, S. A. (2018) · Cambridge University Press eBooks · doi:10.1017/9781108149938.011
Pilz, S., & März, W. (2020) · Der Klinikarzt · doi:10.1055/a-1237-0965
Hamidi, M., Mavros, M. N., Devon, K. M., Kulkarni, G. S., Law, C., Urbach, D. R., Hallet, J. I., & Pasternak, J. D. (2020) · Springer eBooks · doi:10.1007/978-3-030-48363-0_1 · Cited by 1
Malhotra, S. (2020) · Springer eBooks · doi:10.1007/978-3-030-52215-5_19
Overview and Initial Management of Cushing Syndrome
Youssef, S., & Singhal, V. (2020) · Springer eBooks · doi:10.1007/978-3-030-52215-5_50
Malignant Hypertension and Osteoporotic Fractures in a 15-year-old Boy
Elrokhsi, S. H., Manzo, R. B., Wheeler, M. D., Senguttuvan, R., & Chin, C. N. (2020) · Pediatrics in Review · doi:10.1542/pir.2018-0251
Protocolo diagnóstico de las alteraciones del potasio de origen endocrinológico
Lara-Barea, A., Escandon, L. L., & Tinoco, C. L. (2020) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2020.10.015
Tresoldi, A. S., & Lania, A. G. (2020) · L Endocrinologo · doi:10.1007/s40619-020-00769-1
Metadata
- Authors
- Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M.
- Affiliations
- National Institutes of Health (US)
- Massachusetts General Hospital (US)
- Medical College of Wisconsin (US)
- University of Sheffield (GB)
- Queen Mary University of London (GB)
- University of Birmingham (GB)
- Mayo Clinic (V.M.M.), Rochester, Minnesota 55905
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2008-05-01
- Volume
- 93
- Issue
- 5
- Pages
- 1526-1540
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC2386281
- OpenAlex
- W1990995386
- Cited by
- 2,718
- References
- 140
- Citations by year
- 2026: 159 · 2025: 173 · 2024: 173 · 2023: 148 · 2022: 212 · 2021: 199 · 2020: 195 · 2019: 165 · 2018: 150 · 2017: 148 · 2016: 158 · 2015: 156 · 2014: 134 · 2013: 139 · 2012: 114
- FWCI
- 70.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- European Society of Endocrinology
- National Institutes of Health
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (Z01HD008833)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- Cushing's syndrome, diagnosis, hypercortisolism, adrenal incidentaloma, dexamethasone suppression test, late-night salivary cortisol, urine cortisol
- MeSH terms
- Cushing Syndrome, Dexamethasone, Humans, Hydrocortisone, Saliva, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.